Abbott (ABT) Reports In-Line Q4 EPS; offers guidance

Abbott (NYSE: ABT) reported Q4 EPS of $1.50, in-line with the analyst estimate of $1.50. Revenue for the quarter came in at $11.46 billion versus the consensus estimate of $11.8 billion.

GUIDANCE:

Abbott sees Q1 2026 EPS of $1.12-$1.18, versus the consensus of $1.20.

Abbott sees FY2026 EPS of $5.55-$5.80, versus the consensus of $5.17.

For earnings history and earnings-related data on Abbott (ABT) click here.

You May Also Be Interested In

• Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $55 at Guggenheim
• Opera Limited (OPRA) Misses Q2 EPS by 1c ; Offers Guidance
• Analog Devices (ADI) Tops Q3 EPS by 11c, Beats on Revenue; Offers Q4 Guidance